As expected, the results demonstrated that sCD163 levels in plasma were decreased significantly at various time points during anti-TB therapy, especially at month 9 of treatment, compared with that at the baseline (1180.0 ng/ml vs 685.9 ng/ml, P = 0.0011, Fig. 6). The gene discussed is CD163; the disease is tuberculosis.